

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1. (currently amended) A method of preparing a dry powder inhalation composition comprising the steps of:

(a) mixing a particulate carrier with a first portion of a first particulate inhalant medicament to form a first mixture, wherein said particulate carrier has a volume median diameter (VMD) of from about 50 to about 250 μ m;

(b) mixing said first mixture with a second particulate inhalant medicament to form a second mixture; and

(c) mixing said second mixture with a second portion of the first particulate inhalant medicament to form a dry powder inhalation composition,

wherein, in the dry powder inhalation composition from step (c), the ratio by weight of the second particulate inhalant medicament to the carrier is less than the ratio by weight of the first particulate inhalant medicament to the carrier.

2. (previously presented) A method according to claim 1, wherein the first portion of the first particulate inhalant medicament is less than half weight by weight of the total amount of the first particulate inhalant medicament in the dry powder inhalation composition.

3. (currently amended) A method according to claim 1, wherein the first portion of first particulate inhalant medicament is less than 2% weight by weight of the total amount of the particulate carrier.

4. (currently amended) A method according to claim 1, wherein the first portion of the first particulate inhalant medicament is sufficient to create a monolayer of the first particulate inhalant medicament on the particulate carrier.

5. (currently amended) A method according to claim 1, wherein the particulate carrier is lactose.

6. (previously presented) A method according to claim 1, wherein the first particulate inhalant medicament is an anti-inflammatory steroid or a pharmaceutically acceptable derivative thereof.

7. (currently amended) A method according to ~~claims~~ claim 1, 5 or 6, wherein the first particulate inhalant medicament is budesonide or a pharmaceutically acceptable derivative thereof.

8. (currently amended) A method according to ~~claims~~ claim 1 or 5, wherein the second particulate inhalant ~~second~~ medicament is a bronchodilator or a pharmaceutically acceptable derivative thereof.

9. (currently amended) A method according to ~~claims~~ claim 1, 5 or 6, wherein the second particulate ~~inhalant medicament~~ inhalant medicament is formoterol or a pharmaceutically acceptable derivative thereof.

10. (previously presented) A method according to claim 1, wherein the ratio of the first particulate inhalant medicament to the second particulate inhalant medicament by weight is from 5:1 to 100:1.

11. (currently amended) A dry powder inhalation composition prepared by a process comprising the steps of:

- (a) mixing a particulate carrier with a first portion of a first particulate inhalant medicament to form an first mixture, wherein said particulate carrier has a volume median diameter (VMD) of from about 50 to about 250 μ m;
- (b) mixing said first mixture with a second particulate inhalant medicament to form a second mixture; and
- (c) mixing said second mixture with a second portion of the first particulate inhalant medicament to form a dry powder inhalation composition,

wherein, in the dry powder inhalation composition from step (c), the ratio by weight of the second particulate inhalant medicament to the carrier is less than the ratio by weight of the first particulate inhalant medicament to the carrier, and wherein the dry powder inhalation composition consists of said particulate carrier, said first particulate inhalant medicament and said second particulate inhalant medicament.

12. (previously presented) A dry powder inhalation composition according to claim 11, wherein the first particulate inhalant medicament is budesonide or a pharmaceutically acceptable derivative thereof.

13. (currently amended) A dry powder inhalation composition according to claim 11, wherein the second particulate inhalant medicament is formoterol fumarate ~~anhydrous~~ dihydrate.

14. (currently amended) A MDPI comprising a composition according to any one of claims 11-13.

15. (previously presented) A method for the administration of a particulate medicament, comprising inhalation from a multidose dry powder inhaler of a composition of any one of claims 11-13.

16. (New) The method of claim 1, wherein the dry powder inhalation composition of step (c) consists of said particulate carrier, said first particulate inhalant medicament and said second particulate inhalant medicament.

17. (New) A dry powder inhalation composition according to claim 11, wherein said particulate carrier has a VMD of from about 50 to about 60 μm .

18. (New) A dry powder inhalation composition according to claim 11, wherein said particulate carrier has a VMD of from about 60 to about 90 μm .

19. (New) A dry powder inhalation composition according to claim 11, wherein said particulate carrier has a VMD of from about 90 to about 150 μm .